Free tool
FAERS Monitor: Thioguanine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 012429 or its brand name (Thioguanine, Thioguanine). Reports on generic versions are filed under their own applications.
Reports
2,126
Serious
2,020
95% of reports
Hospitalization
983
Death reported
376
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia493
- neutropenia141
- haematotoxicity138
- pyrexia134
- off label use123
- sepsis103
- thrombocytopenia101
- vomiting91
- pancytopenia86
- febrile bone marrow aplasia70
- venoocclusive liver disease70
- mucosal inflammation68
- platelet count decreased67
- death61
- nausea59
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 30 |
| 2005 | 33 |
| 2006 | 57 |
| 2007 | 39 |
| 2008 | 43 |
| 2009 | 54 |
| 2010 | 73 |
| 2011 | 50 |
| 2012 | 56 |
| 2013 | 44 |
| 2014 | 181 |
| 2015 | 79 |
| 2016 | 59 |
| 2017 | 110 |
| 2018 | 184 |
| 2019 | 158 |
| 2020 | 108 |
| 2021 | 123 |
| 2022 | 210 |
| 2023 | 157 |
| 2024 | 124 |
| 2025 | 105 |
| 2026 | 49 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,033 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile bone marrow aplasiaSignal | 70 | 165.7 | 131.3 | 11,109 |
| haematotoxicitySignal | 138 | 145.8 | 123.9 | 19,420 |
| venoocclusive liver diseaseSignal | 70 | 142.2 | 112.8 | 9,542 |
| febrile neutropeniaSignal | 493 | 74.1 | 68.5 | 35,312 |
| mucosal inflammationSignal | 68 | 25.8 | 20.4 | 1,592 |
| pancytopeniaSignal | 86 | 15.2 | 12.4 | 1,132 |
| neutropeniaSignal | 141 | 10.3 | 8.8 | 1,177 |
| sepsisSignal | 103 | 9.1 | 7.6 | 742 |
| thrombocytopeniaSignal | 101 | 8.9 | 7.4 | 708 |
| platelet count decreasedSignal | 67 | 6.2 | 4.9 | 290 |
| pyrexiaSignal | 134 | 3.8 | 3.3 | 282 |
| vomiting | 91 | 1.9 | 1.6 | 40 |
| off label use | 123 | 1.4 | 1.2 | 14 |
| nausea | 59 | 0.7 | 0.6 | 5 |
| death | 61 | 0.7 | 0.5 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.